Pascal Hammel

3.4k total citations · 1 hit paper
21 papers, 2.0k citations indexed

About

Pascal Hammel is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pascal Hammel has authored 21 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 8 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pascal Hammel's work include Pancreatic and Hepatic Oncology Research (15 papers), PARP inhibition in cancer therapy (10 papers) and Cancer Genomics and Diagnostics (8 papers). Pascal Hammel is often cited by papers focused on Pancreatic and Hepatic Oncology Research (15 papers), PARP inhibition in cancer therapy (10 papers) and Cancer Genomics and Diagnostics (8 papers). Pascal Hammel collaborates with scholars based in France, United States and Spain. Pascal Hammel's co-authors include Eric Van Cutsem, Teresa Macarulla, Talia Golan, Michele Reni, Michael J. Hall, Do‐Youn Oh, Daniel Hochhauser, Gershon Y. Locker, Hedy L. Kindler and David McGuinness and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and International Journal of Cancer.

In The Last Decade

Pascal Hammel

21 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

2019 1.5k citations Talia Golan, Pascal Hammel et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pascal Hammel France	12	1.8k	882	687	387	213	21	2.0k
Karen Cui United States	8	1.6k 0.9×	820 0.9×	729 1.1×	367 0.9×	230 1.1×	29	1.9k
J. S. Reis-Filho United Kingdom	14	1.0k 0.6×	884 1.0×	812 1.2×	309 0.8×	314 1.5×	24	2.0k
Ana De Jesus‐Acosta United States	21	1.4k 0.8×	567 0.6×	600 0.9×	395 1.0×	73 0.3×	76	1.9k
Russell Bonneville United States	11	773 0.4×	611 0.7×	605 0.9×	503 1.3×	82 0.4×	16	1.6k
Timothy Pluard United States	20	1.3k 0.7×	772 0.9×	534 0.8×	751 1.9×	125 0.6×	80	1.9k
Dexter X. Jin United States	17	756 0.4×	439 0.5×	575 0.8×	373 1.0×	66 0.3×	46	1.5k
Alexander C. Klimowicz Canada	23	653 0.4×	280 0.3×	821 1.2×	188 0.5×	131 0.6×	56	1.5k
Jonathan C. Dudley United States	15	937 0.5×	625 0.7×	380 0.6×	495 1.3×	48 0.2×	24	1.5k
Yi-Zhou Jiang China	23	648 0.4×	827 0.9×	681 1.0×	282 0.7×	83 0.4×	41	1.5k
David Huntsman Canada	17	681 0.4×	377 0.4×	567 0.8×	295 0.8×	110 0.5×	28	1.4k

Countries citing papers authored by Pascal Hammel

Since Specialization

Citations

This map shows the geographic impact of Pascal Hammel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Hammel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Hammel more than expected).

Fields of papers citing papers by Pascal Hammel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Hammel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Hammel. The network helps show where Pascal Hammel may publish in the future.

Co-authorship network of co-authors of Pascal Hammel

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Hammel. A scholar is included among the top collaborators of Pascal Hammel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Hammel. Pascal Hammel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Golan, Talia, Raffaella Casolino, Andrew V. Biankin, et al.. (2023). Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Therapeutic Advances in Medical Oncology. 15. 2633863–2633863. 10 indexed citations

Kindler, Hedy L., Pascal Hammel, Michele Reni, et al.. (2022). Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Journal of Clinical Oncology. 40(34). 3929–3939. 120 indexed citations

Perkhofer, Lukas, Talia Golan, Pieter‐Jan Cuyle, et al.. (2021). Targeting DNA Damage Repair Mechanisms in Pancreas Cancer. Cancers. 13(17). 4259–4259. 17 indexed citations

Schwartz, Lawrence H., Hedy L. Kindler, Pascal Hammel, et al.. (2021). POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. Journal of Clinical Oncology. 39(3_suppl). 412–412. 1 indexed citations

Golan, Talia, Pascal Hammel, Michele Reni, et al.. (2021). Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.. Journal of Clinical Oncology. 39(3_suppl). 378–378. 59 indexed citations

Hammel, Pascal, Rossana Berardi, G.J. Creemers, et al.. (2020). TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).. Journal of Clinical Oncology. 38(15_suppl). TPS4666–TPS4666. 3 indexed citations

Reni, Michele, Hedy L. Kindler, Pascal Hammel, et al.. (2020). Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.. Journal of Clinical Oncology. 38(4_suppl). 686–686. 1 indexed citations

Macarulla, Teresa, Hedy L. Kindler, Pascal Hammel, et al.. (2020). Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P).. Journal of Clinical Oncology. 38(4_suppl). 750–750. 1 indexed citations

Hall, Michael J., Talia Golan, Pascal Hammel, et al.. (2020). Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. Journal of Clinical Oncology. 38(4_suppl). 648–648. 3 indexed citations

10.

Tempero, Margaret A., Eric Van Cutsem, Darren Sigal, et al.. (2020). HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).. Journal of Clinical Oncology. 38(4_suppl). 638–638. 93 indexed citations

11.

Collard, M., Nathalie Guedj, Miguel Albuquerque, et al.. (2020). Immune-checkpoint inhibitor anti-PD1 aggravates colitis-associated colorectal cancer without enhancing intestinal inflammation. 7(2). 1 indexed citations

12.

Golan, Talia, Pascal Hammel, Michele Reni, et al.. (2019). Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine. 381(4). 317–327. 1468 indexed citations breakdown →

13.

Seufferlein, Thomas, Pascal Hammel, Jean‐Robert Delpéro, et al.. (2019). Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Cancer Treatment Reviews. 77. 1–10. 40 indexed citations

14.

Kindler, Hedy L., Pascal Hammel, Michele Reni, et al.. (2019). Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.. Journal of Clinical Oncology. 37(18_suppl). LBA4–LBA4. 10 indexed citations

15.

Golan, Talia, Hedy L. Kindler, Joon Oh Park, et al.. (2018). Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 36(15_suppl). 4115–4115. 12 indexed citations

16.

Cutsem, Eric Van, Manuel Hidalgo, Jean‐Luc Canon, et al.. (2018). Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. International Journal of Cancer. 143(8). 2053–2064. 74 indexed citations

17.

Cutsem, Eric Van, Manuel Hidalgo, I. Bazin, et al.. (2015). Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology. 33(3_suppl). 344–344. 19 indexed citations

18.

Golan, Talia & Pascal Hammel. (2014). Making Gay Okay. PubMed. 19(4). 469–473. 4 indexed citations

19.

Goldstein, David, Robert H. El-Maraghi, Pascal Hammel, et al.. (2014). Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).. Journal of Clinical Oncology. 32(15_suppl). 4027–4027. 11 indexed citations

20.

Goldstein, David, Pascal Hammel, Volker Heinemann, et al.. (2014). Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. Journal of Clinical Oncology. 32(3_suppl). 178–178. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact